title: Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
abstract: Hodgkin lymphoma (HL) relapsing after allogeneic stem cell transplantation (alloSCT) presents a major clinical challenge. In the present investigation, we evaluated brentuximab vedotin, a CD30-directed Ab-drug conjugate, in 25 HL patients (median age, 32 years; range, 20-56) with recurrent disease after alloSCT (11 unrelated donors). Patients were > 100 days after alloSCT, had no active GVHD, and received a median of 9 (range, 5-19) prior regimens. Nineteen (76%) had refractory disease immediately before enrollment. Patients received 1.2 or 1.8 mg/kg of brentuximab vedotin IV every 3 weeks (median, 8 cycles; range, 1-16). Overall and complete response rates were 50% and 38%, respectively, among 24 evaluable patients. Median time to response was 8.1 weeks, median progression-free survival was 7.8 months, and the median overall survival was not reached. Cough, fatigue, and pyrexia (52% each), nausea and peripheral sensory neuropathy (48% each), and dyspnea (40%) were the most frequent adverse events. The most common adverse events ≥ grade 3 were neutropenia (24%), anemia (20%), thrombocytopenia (16%), and hyperglycemia (12%). Cytomegalovirus was detected in 5 patients (potentially clinically significant in 1). These results support the potential utility of brentuximab vedotin for selected patients with HL relapsing after alloSCT.
authors.affiliation: University of Washington/Seattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle,WA 98195, USA. agopal@u.washington.edu
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
authors.forename: Radhakrishnan
authors.initials: R
authors.lastname: Ramchandren
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
authors.forename: Robert B
authors.initials: RB
authors.lastname: Berryman
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.forename: Scott E
authors.initials: SE
authors.lastname: Smith
authors.forename: Maureen
authors.initials: M
authors.lastname: Cooper
authors.forename: Achim
authors.initials: A
authors.lastname: Rothe
authors.forename: Jeffrey V
authors.initials: JV
authors.lastname: Matous
authors.forename: Laurie E
authors.initials: LE
authors.lastname: Grove
authors.forename: Jasmine
authors.initials: J
authors.lastname: Zain
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects; D007239:Infections / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D011446:Prospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin